MedTrace Logo

Clinical Trial of PCV24 in Adults Aged ≥18 Years

NCT07543198 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2026-04-21

No results posted yet for this study

Summary

A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years.

The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, Positive Controlled phase Ib/II clinical trial.

Conditions

  • Pneumococcal Infectious Disease

Interventions

BIOLOGICAL

Sinovac Low-dosage PCV24

One dose of Sinovac Low-dosage PCV24 (0.5mL)

BIOLOGICAL

Sinovac Middle-dosage PCV24

One dose of Sinovac Middle-dosage PCV24(0.5mL)

BIOLOGICAL

Sinovac High-dosage PCV24

One dose of Sinovac High-dosage PCV24(0.5mL)

BIOLOGICAL

Pneumovax®

One dose of PPV23 manufactured by MSD

Sponsors & Collaborators

  • Sinovac Life Sciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weijun Hu · Shaanxi Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-18
Primary Completion
2026-02-26
Completion
2026-02-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07543198 on ClinicalTrials.gov